2-amino-9-pentyl-3H-purine-6-thione profile

ID Source	ID
PubMed CID	3003779
CHEMBL ID	53268
CHEBI ID	112688
SCHEMBL ID	14358967

Synonym
24397-98-6
nsc58907
nsc-58907
mls000737341 ,
2-amino-9-pentyl-9h-purin-6-yl hydrosulfide
2-amino-9-pentyl-9h-purine-6-thiol
2-amino-9-pentyl-purine-6-thiol
smr000528272
CHEBI:112688
CHEMBL53268
2-amino-9-pentyl-3h-purine-6-thione
NCGC00246842-01
HMS2885H17
sob0830079 ,
nsc 58907
2-amino-9-pentyl-6-purinethiol
unii-sob0830079
SCHEMBL14358967
Q27192802
DTXSID20179141
6h-purine-6-thione, 2-amino-1,9-dihydro-9-pentyl-
9h-purine-6-thiol, 2-amino-9-pentyl-
2-amino-1,9-dihydro-9-pentyl-6h-purine-6-thione

Class	Description
purines	A class of imidazopyrimidines that consists of purine and its substituted derivatives.
thiocarbonyl compound	Any compound containing the thiocarbonyl group, C=S.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolase	Giardia intestinalis	Potency	2.8117	0.1409	11.1940	39.8107	AID2451
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	17.7828	0.6310	35.7641	100.0000	AID504339
phosphopantetheinyl transferase	Bacillus subtilis	Potency	2.5119	0.1413	37.9142	100.0000	AID1490
TDP1 protein	Homo sapiens (human)	Potency	8.1995	0.0008	11.3822	44.6684	AID686978
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	3.5481	0.7079	12.1943	39.8107	AID720542
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	89.1251	0.7079	36.9043	89.1251	AID504333
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	8.9125	0.0355	20.9770	89.1251	AID504332
chromobox protein homolog 1	Homo sapiens (human)	Potency	50.1187	0.0060	26.1688	89.1251	AID540317
serine/threonine-protein kinase PLK1	Homo sapiens (human)	Potency	23.7781	0.1683	16.4040	67.0158	AID720504
histone-lysine N-methyltransferase 2A isoform 2 precursor	Homo sapiens (human)	Potency	1.4125	0.0103	23.8567	63.0957	AID2662
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	19.1499	0.0079	8.2332	1,122.0200	AID2546; AID2551
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	7.5686	0.0601	10.7453	37.9330	AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID97709	Percentage of viable L1210 leukemia cells killed by single treatment with the compound	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Sulfinosine congeners: synthesis and antitumor activity in mice of certain N9-alkylpurines and purine ribonucleosides.
AID120707	Antileukemic activity in BD2F1 mice inoculated with 1 x 10E6 L1210 cells.	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Sulfinosine congeners: synthesis and antitumor activity in mice of certain N9-alkylpurines and purine ribonucleosides.
AID112127	Maximum soluble dosage which induces toxicity in mice when administered intraperitoneally was determined	1994	Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1	Sulfinosine congeners: synthesis and antitumor activity in mice of certain N9-alkylpurines and purine ribonucleosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (16.67)	18.2507
2000's	1 (16.67)	29.6817
2010's	3 (50.00)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Leukemia L 1210 [description not available]	1.98	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1

2-amino-9-pentyl-3H-purine-6-thione

Cross-References

Synonyms (23)

Drug Classes (2)

Protein Targets (12)

Potency Measurements

Bioassays (15)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.87

Study Types

2-amino-9-pentyl-3H-purine-6-thione

Cross-References

Synonyms (23)

Drug Classes (2)

Protein Targets (12)

Potency Measurements

Bioassays (15)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.87

Study Types

Related Conditions (3)